Thanks for the update!Nasrat mentioned during our most recent conference call again that we have "several"(4+) more of these needle mover $Billion dollar drugs in our pipeline.This is why we will be in dollar land soon.Good luck to all of you long and strong loyal ELTP investors out here!
***** MUST READ *****
November 15, 2023 Conference Call:
Nasrat: "I've made the decision for the company that going forward, we are no longer going to work on small products. And what I mean by that is, like the product I was alluding to earlier, the dopamine agonist, it is a very small product. It takes a lot of effort to work on small products. It takes a lot more effort to work on larger products, but larger products really pay. In way of an example we had about 250 products at the Elizabeth facility. Out of the 250, 12 of them were bringing in 80% of the money and the rest were fillers. Well, we are a small company. So going forward, every single product you are going to select is going to be a large billion-dollar product."
"So the three products we have in development right now are at the early stage. All of them are product that we have selected that fits within our technology, either tablets, capsules, extended release, instant release. And they need to be either going to be off patent soon or have a very good market. And we have three of these products identified that we will be working on for the next generation. And I'll keep you updated on that. These three products that we're starting on other than the five I updated you on, are all products that are still on patent for a couple of more years, and each and every one of them is a $1 billion market or above."
Bullish
AI
Market Data 
Markets 
